Answer: Membrane transport proteins are specific and selective for the molecules they move, and they often use energy to catalyze passage. Also, these proteins transport some nutrients against the concentration gradient, which requires additional energy.
Explanation:
What process occurs to in the first stage of celluar respiration?
The first stage is called glycolysis. Glycolysis is a process that uses sugar to create ATP molecules
I believe <u>B.) Analogous structures show that living in similar habitats doesn't lead to similar adaptations </u>is your right answer.
Answer: a) substrate and cofactors b) covalent modification
Explanation:
Metabolic pathways involve all the chemical processes takes place in the enviornment or in an organisms.The metabolic pathways are controlled through the catalytic activities of enzymes.
The availability of enzyme is regulated by substrate and cofactors present in enzyme and enzyme activity is commonly regulated via covalent modification.
Enzymes are highly selective in nature and bind to a specific substarte only. The active site in enzyme binds with the substrate to form enzyme substrate complex. Coactors assist the enzyme activity, without cofactor enzyme can not perform its activity.
Hence enzyme availibility is regulated by substrate and cofactors regulates.
Covalent modifications regulates activity of enzyme as it involves addition and removal of chemical group to synthesis required protein. It can change the chemical properties of the site by targeting one or multiple amino acid.
Thus the correct answer is a) substrate and cofactors b) covalent modification
Answer:
Explanation:
The more similar the two species are, the more their niche overlaps and the more competition there is.
<em>The most interesting results obtained in animal models of passive immunotherapies developed according to the “amyloid-beta cascade hypothesis” and the “Tau hypothesis” are monoclonal antibodies that directly or indirectly target Aβ plaques or neurofibrillary tangles. Unfortunately, these therapeutic antibodies cannot replicate their promising effects on humans at the clinical phase. Despite this, we still hope to learn from these failures and to explore new pathways. The great effects obtained in animals with passive immunotherapy suggest that this technology may be an important key to curative treatment. The remaining challenge is to find a way to achieve the same encouraging results for humans. Alzheimacy expects to join hands with global partners to focus on the development of therapeutic antibodies for Alzheimer’s disease (AD) and continue to fight against this disease.</em>
<em>https://www.creativebiomart.net/alzheimacy/therapeutics/therapeutic-antibody/</em>